The overall goal of the Clinical Core is to generate data and biospecimens required to support high quality, cutting edge, externally-funded clinical and clinical-pathologic studies that focus on the full spectrum of cognition from normal aging to mild cognitive impairment (MCI) to the earliest stages of dementia among older African Americans. Historically, progress in Alzheimer's disease (AD) research has been most striking among members of the U.S. non-Hispanic white population. However, because of the expected increase in the growth of the older African American population, because African Americans may be at greater risk of AD than whites, and the burden of AD and mixed dementias is projected to increase dramatically for this population, the Rush Clinical Core will focus on enrolling and following African Americans longitudinally to accomplish the following Specific Aims: 1) Continue to recruit and enroll African Americans without dementia who agree to annual, detailed clinical evaluations and collection of ante-mortem biologic specimens;2) Continue to conduct uniform structured baseline and annual follow-up evaluations, including neurological examination and neuropsychological performance testing, of community-dwelling Clincal Core participants, apply uniform diagnostic criteria for incident AD, MCI, and mixed dementias as specified in the UDS, and supplement UDS data collection with an extended battery of tests to increase compatibility with the Religious Orders Studies Core;3) Integrate innovative and culturally tailored educational programs into the clinical evaluation to increase awareness of the importance of brain autopsy in African Americans and to facilitate a high autopsy rate with a short post-mortem interval;and continue to harvest and preserve the brain tissue in a fashion that retains maximum flexibility to support a diverse array of studies;and 4) Increase capacity to conduct externally funded clinical, neuropsychological, and clinical-pathological research studies, including studies that incorporate contemporary biochemical and molecular techniques, by contributing data to NACC and providing an environment and resources to facilitate entry of subjects, clinical data, and post-mortem tissue into research projects at Rush and within the AD research community at large.
The Rush Clinical Core will generate data and biospecimens to support high quality, cutting edge clinical and clinical-pathologic studies that focus on the full spectrum of cognition in older African Americans, one of the fastest growing populations in the U.S. Knowledge gained through studies supported by the Core will advance our understanding of the clinical and neuropathoiogic transitions from normal cognition to dementia.
|Brenowitz, Willa D; Keene, C Dirk; Hawes, Stephen E et al. (2017) Alzheimer's disease neuropathologic change, Lewy body disease, and vascular brain injury in clinic- and community-based samples. Neurobiol Aging 53:83-92|
|Bernier, Patrick J; Gourdeau, Christian; Carmichael, Pierre-Hugues et al. (2017) Validation and diagnostic accuracy of predictive curves for age-associated longitudinal cognitive decline in older adults. CMAJ 189:E1472-E1480|
|Buchman, Noa M; Leurgans, Sue E; Shah, Raj J et al. (2017) Urinary Incontinence, Incident Parkinsonism, and Parkinson's Disease Pathology in Older Adults. J Gerontol A Biol Sci Med Sci 72:1295-1301|
|Sposato, Luciano A; Ruíz Vargas, Estefanía; Riccio, Patricia M et al. (2017) Milder Alzheimer's disease pathology in heart failure and atrial fibrillation. Alzheimers Dement 13:770-777|
|Moga, Daniela C; Abner, Erin L; Wu, Qishan et al. (2017) Bladder antimuscarinics and cognitive decline in elderly patients. Alzheimers Dement (N Y) 3:139-148|
|Klaver, Andrea C; Coffey, Mary P; Bennett, David A et al. (2017) Specific serum antibody binding to phosphorylated and non-phosphorylated tau in non-cognitively impaired, mildly cognitively impaired, and Alzheimer's disease subjects: an exploratory study. Transl Neurodegener 6:32|
|Yu, Lei; Dawe, Robert J; Buchman, Aron S et al. (2017) Ex vivo MRI transverse relaxation in community based older persons with and without Alzheimer's dementia. Behav Brain Res 322:233-240|
|Ahmad, Faraz; Singh, Kunal; Das, Debajyoti et al. (2017) Reactive Oxygen Species-Mediated Loss of Synaptic Akt1 Signaling Leads to Deficient Activity-Dependent Protein Translation Early in Alzheimer's Disease. Antioxid Redox Signal 27:1269-1280|
|Sennik, Simrin; Schweizer, Tom A; Fischer, Corinne E et al. (2017) Risk Factors and Pathological Substrates Associated with Agitation/Aggression in Alzheimer's Disease: A Preliminary Study using NACC Data. J Alzheimers Dis 55:1519-1528|
|Burke, Shanna L; O'Driscoll, Janice; Alcide, Amary et al. (2017) Moderating risk of Alzheimer's disease through the use of anxiolytic agents. Int J Geriatr Psychiatry 32:1312-1321|
Showing the most recent 10 out of 689 publications